Figure 2

The effects of BAY-747 and runcaciguat on L-NAME induced short-term memory impairments. Vehicle animals showed healthy memory performance which was significantly higher than virtual zero (independent-samples t test), whereas L-NAME treated animals showed poor memory performance which was significantly lower than vehicle treated animals (independent-samples t test) and not significant from zero. Treatment with 0.3 mg/kg BAY-747 reversed L-NAME induced memory impairments since the discrimination index was both significantly higher compared to virtual zero and L-NAME treated animals (one-way ANOVA). Treatment with 1.0 mg/kg BAY-747 did not alter short-term memory performance after L-NAME treatment. Runcaciguat was unable to enhance memory performance under L-NAME treated conditions in the doses tested. Both BAY-747 and runcaciguat were administered p.o. at 2 ml/kg 30 min before T1 in a 1 h interval OLT. L-NAME was administered for 6 consecutive days at 30 mg/kg p.o. and administered 1 h before T1 on testing days. Hashes represent a significant difference from virtual zero (0 ± 0.05) as measured with independent-sample t tests, ^##P < 0.01; ^###P < 0.001. Asterisks represent a significant difference from L-NAME, *P < 0.05; **P < 0.01. Data are represented as mean + SEM.